Jiaping He

1.0k total citations
23 papers, 555 citations indexed

About

Jiaping He is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Jiaping He has authored 23 papers receiving a total of 555 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Immunology. Recurrent topics in Jiaping He's work include CAR-T cell therapy research (13 papers), Virus-based gene therapy research (3 papers) and Biosimilars and Bioanalytical Methods (3 papers). Jiaping He is often cited by papers focused on CAR-T cell therapy research (13 papers), Virus-based gene therapy research (3 papers) and Biosimilars and Bioanalytical Methods (3 papers). Jiaping He collaborates with scholars based in China and Japan. Jiaping He's co-authors include Wei Cao, Xun Ye, Lianjun Shen, Zhenguang Wang, Meixia Chen, Haoyi Wang, Weidong Han, Qingming Yang, Jing Nie and Yan Zhang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jiaping He

23 papers receiving 548 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiaping He China 12 384 212 121 119 93 23 555
Youbin Zhang United States 16 251 0.7× 374 1.8× 216 1.8× 57 0.5× 52 0.6× 60 750
Xiaohui Si China 13 228 0.6× 200 0.9× 62 0.5× 121 1.0× 102 1.1× 29 467
Quande Lin China 10 327 0.9× 273 1.3× 95 0.8× 108 0.9× 101 1.1× 35 601
Dennis F.G. Remst Netherlands 12 237 0.6× 377 1.8× 78 0.6× 37 0.3× 161 1.7× 25 817
Filippo Rossignoli United States 11 187 0.5× 221 1.0× 73 0.6× 82 0.7× 145 1.6× 18 582
Mohsen Sheykhhasan Iran 13 186 0.5× 214 1.0× 43 0.4× 45 0.4× 89 1.0× 35 557
Mauro P. Avanzi United States 13 491 1.3× 184 0.9× 154 1.3× 149 1.3× 156 1.7× 22 684
Katharina Zimmermann Germany 12 433 1.1× 177 0.8× 149 1.2× 99 0.8× 402 4.3× 17 733
Rosa M. Gonzalo‐Daganzo Spain 10 135 0.4× 61 0.3× 45 0.4× 46 0.4× 111 1.2× 11 403

Countries citing papers authored by Jiaping He

Since Specialization
Citations

This map shows the geographic impact of Jiaping He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiaping He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiaping He more than expected).

Fields of papers citing papers by Jiaping He

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiaping He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiaping He. The network helps show where Jiaping He may publish in the future.

Co-authorship network of co-authors of Jiaping He

This figure shows the co-authorship network connecting the top 25 collaborators of Jiaping He. A scholar is included among the top collaborators of Jiaping He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiaping He. Jiaping He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Xinfeng, Ping Yu, Ling Li, et al.. (2023). CD19/BCMA Dual-Targeting Fastcar-T GC012F for Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: An Update. Blood. 142(Supplement 1). 6847–6847. 1 indexed citations
2.
Fu, Weijun, Baoxia Dong, Gao Li, et al.. (2023). P869: UPDATED RESULTS OF A PHASE I, OPEN-LABEL STUDY OF BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM). HemaSphere. 7(S3). e84060bf–e84060bf. 6 indexed citations
3.
Yang, Junfang, Jiaping He, Xian Zhang, et al.. (2022). Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood Cancer Journal. 12(7). 104–104. 69 indexed citations
4.
Li, Shiqi, Xinxin Wang, Lin Liu, et al.. (2022). Abstract CT196: Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Cancer Research. 82(12_Supplement). CT196–CT196. 4 indexed citations
5.
Wang, Zhenguang, Na Li, Kaichao Feng, et al.. (2021). Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cellular and Molecular Immunology. 18(9). 2188–2198. 177 indexed citations
6.
He, Jiaping, et al.. (2021). Fast A* Anchor Point based Path Planning for Narrow Space Parking. 1604–1609. 6 indexed citations
7.
Chang, Renjie, et al.. (2020). Ghrelin inhibits IKKβ/NF-κB activation and reduces pro-inflammatory cytokine production in pancreatic acinar AR42J cells treated with cerulein. Hepatobiliary & pancreatic diseases international. 20(4). 366–375. 8 indexed citations
8.
Tan, Shuo, Yuan Chen, Yue Gao, et al.. (2020). β-Galactosidase gene codon optimization results in post-transcriptional enhancement of expression. Gene. 748. 144676–144676. 3 indexed citations
9.
Wang, Xinxin, Shiqi Li, Lei Gao, et al.. (2020). Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).. Journal of Clinical Oncology. 38(15_suppl). 3013–3013. 9 indexed citations
10.
Yang, Junfang, Pengfei Jiang, Xian Zhang, et al.. (2020). Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood. 136(Supplement 1). 2–3. 12 indexed citations
11.
Yang, Junfang, Pengfei Jiang, Xian Zhang, et al.. (2019). Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia. Blood. 134(Supplement_1). 284–284. 21 indexed citations
12.
Zhang, Hua, Lei Gao, Li Liu, et al.. (2019). A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma. Blood. 134(Supplement_1). 3147–3147. 43 indexed citations
13.
Zhang, Cheng, Jiaping He, Li Liu, et al.. (2019). CD19-Directed Fast CART Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia: From Bench to Bedside. Blood. 134(Supplement_1). 1340–1340. 13 indexed citations
14.
Yang, Junfang, Jiaping He, Xian Zhang, et al.. (2019). A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia. Blood. 134(Supplement_1). 825–825. 16 indexed citations
15.
Zhou, Jie, et al.. (2018). Cav 1.2 and Cav 2.2 expression is regulated by different endogenous ghrelin levels in pancreatic acinar cells during acute pancreatitis. International Journal of Molecular Medicine. 41(5). 2909–2916. 2 indexed citations
16.
Feng, Chenchen, Xuan Luo, Na He, et al.. (2017). Efficacy and Persistence of Allogeneic Adipose-Derived Mesenchymal Stem Cells Combined with Hyaluronic Acid in Osteoarthritis After Intra-articular Injection in a Sheep Model. Tissue Engineering Part A. 24(3-4). 219–233. 59 indexed citations
17.
He, Jiaping. (2016). Role of myosin light chain kinase in hypertriglyceridemia-associated acute pancreatitis in rats. World Chinese Journal of Digestology. 24(1). 19–19. 1 indexed citations
18.
Wang, Wen, Na He, Chenchen Feng, et al.. (2015). Human Adipose-Derived Mesenchymal Progenitor Cells Engraft into Rabbit Articular Cartilage. International Journal of Molecular Sciences. 16(6). 12076–12091. 43 indexed citations
19.
He, Jiaping, et al.. (2013). [Establishment of the methodology for quantifying lentiviral vector transcriptional read-through rate].. PubMed. 29(7). 1006–15. 2 indexed citations
20.
He, Jiaping, Isao Usui, Yukiko Kanatani, et al.. (2008). Long-term Interleukin-1α Treatment Inhibits Insulin Signaling via IL-6 Production and SOCS3 Expression in 3T3-L1 Adipocytes. Hormone and Metabolic Research. 40(1). 8–12. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Youbin Zhang Breakdown of academic impact, for papers by Xiaohui Si Breakdown of academic impact, for papers by Quande Lin Breakdown of academic impact, for papers by Dennis F.G. Remst Breakdown of academic impact, for papers by Filippo Rossignoli Breakdown of academic impact, for papers by Mohsen Sheykhhasan Breakdown of academic impact, for papers by Mauro P. Avanzi Breakdown of academic impact, for papers by Katharina Zimmermann Breakdown of academic impact, for papers by Rosa M. Gonzalo‐Daganzo
Rankless by CCL
2026